ClinicalTrials.gg

Program

Ethanol

Also written as “Alcohol”, “Dehydrated Alcohol Injection, USP” and “hand antiseptic with CHG and alcohol”.

Its studies are mostly in Essential Hypertension · Hypertension · Driving Under the Influence · Sleep Initiation and Maintenance Disorders · Fasting, led by 3 companies.

Furthest: phase 3, since Sep 16, 20165 company-led studies, 2 open or runningNext primary completion: May 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ablative Solutions32 open or runningphase 3since Sep 16, 2016Sep 16, 2016May 2028phase 3 · NCT07083765
american-medical-systems10 open or runningphase 2since May 15, 2002May 15, 2002none ahead
Orfagen10 open or runningphase 2since Apr 16, 2007Apr 16, 2007none ahead

Also a collaborator on its studies: 3m, Knoa Pharma and benu-biopharma-llc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 15, 2002First study: phase 2 study in Prostatic DiseasesNew to american-medical-systemsamerican-medical-systems · NCT00037141 · 150 enrolled
  2. Apr 16, 2007Orfagen's first study: phase 2 study in Congenital Venous MalformationNew to OrfagenOrfagen · NCT00462462 · 32 enrolled · United States, France
  3. Sep 16, 2016Ablative Solutions's first study: phase 3 study in HypertensionNew to Ablative SolutionsAblative Solutions · NCT02910414 · 300 enrolled · United States
  4. Mar 23, 2018Phase 2 study in HypertensionAblative Solutions · NCT03503773 · 350 enrolled · Belgium, France, Germany and more
  5. May 12, 2025Phase 3 study in HypertensionAblative Solutions · NCT07083765 · 202 planned · United States

Ahead

  1. May 2028Primary completion: phase 3 study in HypertensionAblative Solutions · NCT07083765

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07083765Hypertension · United States3Not yet recruitingAblative SolutionsMay 2028202
NCT03503773Hypertension · Belgium, France, Germany and more2CompletedAblative SolutionsJan 31, 2022350
NCT02910414Hypertension · United States3Active, not recruitingAblative SolutionsDec 2023300
NCT00462462Congenital Venous Malformation · United States, France2CompletedOrfagenJun 201032
NCT00037141Prostatic Diseases2Completedamerican-medical-systems150

How it is read

Names in the registry

  • “Ethanol”, 4 entries
  • “Alcohol”, 3 entries
  • “Dehydrated Alcohol Injection, USP”, 1 entry
  • “hand antiseptic with CHG and alcohol”, 1 entry
  • “Dehydrated alcohol”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.